PFE
Pfizer Inc
Pfizer Inc historical holders
total: 18
Hillman Value Fund Pfizer Inc transactions over time
- Total transactions:
- 10
- New positions:
- 2
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 4
- Held since:
- 2023 Q4
- Held for:
- 10 quarters
- Latest activity:
- 2025 Q4
Mark A. Hillman has been an institutional investor in Pfizer Inc (PFE) since 2020 Q1. According to 2026 Q1 report, Mark A. Hillman holds 92,700 shares with a market value of roughly $2.60M representing 3.14% of their equity portfolio. The fund/company first acquired PFE in 2020 Q1, initially purchasing 81,500 shares. Mark A. Hillman later completely sold out the position and reinvested in PFE again in 2023 Q4. Since the initial investment, Hillman Value Fund has made 9 more transactions in this position.
Does Mark A. Hillman still hold PFE?
Yes, Mark A. Hillman continues to hold Pfizer Inc (PFE). According to their 2026 Q1 report, they maintain a position of 92,700 shares valued at approximately $2.60M, representing 3.14% of their equity portfolio.
When did Mark A. Hillman first invest in PFE?
Mark A. Hillman first invested in Pfizer Inc (PFE) in 2020 Q1 at the reported quarter-end price of $32.64 per share, acquiring 81,500 shares in their initial purchase.
What is Mark A. Hillman's average cost basis for PFE?
Based on historical transaction data, Mark A. Hillman's estimated cost basis for Pfizer Inc (PFE) is approximately $28.61 per share. This represents their average reported price* across all buy transactions.
Has Mark A. Hillman reinvested in PFE after selling?
Yes, Mark A. Hillman has shown renewed interest in Pfizer Inc (PFE). After completely selling their position, they reinitiated an investment in 2023 Q4, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $28.61
- Weighted AVG sell price:
- $25.22
PFE transactions history by Hillman Value Fund
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q4
|
2.46%
|
92,700
|
$24.90
|
$2,308,230
|
-18.18% (-20,600)
|
-0.49%
|
|
2025 Q3
|
2.75%
|
113,300
|
$25.48
|
$2,886,884
|
-13.51% (-17,700)
|
-0.38%
|
|
2025 Q2
|
2.68%
|
131,000
|
$24.24
|
$3,175,440
|
-5.89% (-8,200)
|
-0.14%
|
|
2025 Q1
|
2.48%
|
139,200
|
$25.34
|
$3,527,328
|
-37.07% (-82,000)
|
-0.98%
|
|
2024 Q1
|
2.53%
|
221,200
|
$27.75
|
$6,138,300
|
+21.53% (+39,191)
|
+0.45%
|
|
2023 Q4
|
2.26%
|
182,009
|
$28.79
|
$5,240,039
|
new
|
+2.26%
|
|
2021 Q4
|
0.00%
|
0
|
$43.01
|
|
-100% (-159,000)
|
-3.17%
|
|
2021 Q1
|
3.33%
|
159,000
|
$36.23
|
$5,760,570
|
+59.80% (+59,500)
|
+1.25%
|
|
2020 Q4
|
2.78%
|
$36.81
|
+22.09% (+18,000)
|
|||
|
2020 Q1
|
3.71%
|
$32.64
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.